Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Early Phase 1

Completed

Conditions: Glioblastoma

Interventions: Drug: Temozolomide
Radiation: Radiation Therapy
Device: NovoTTF-200A Device
Procedure: Tumor Treating Fields Therapy

First Posted Date: 2018-03-26

Last Posted Date: 2024-04-05

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 30

Registration Number: NCT03477110

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Phase 1

Withdrawn

Conditions: Stage IIIB Prostate Cancer
Stage IIIA Prostate Cancer
Stage IV Prostate Cancer
Stage III Prostate Cancer
Stage IIIC Prostate Cancer
Stage IVA Prostate Cancer
Stage IVB Prostate Cancer

Interventions: Biological: Ipilimumab
Radiation: Stereotactic Body Radiation Therapy (SBRT)
Biological: Anti-PD-1 Monoclonal Antibody REGN2810
Procedure: Radical Prostatectomy

First Posted Date: 2018-03-26

Last Posted Date: 2019-11-12

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT03477864

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Refractory B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia

Interventions: Drug: Palbociclib
Drug: Dexamethasone

First Posted Date: 2018-03-21

Last Posted Date: 2024-03-13

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 7

Registration Number: NCT03472573

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Phase 2

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Liver
Metastatic Uveal Melanoma
Stage IV Uveal Melanoma AJCC v7

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Drug: Embolization Therapy

First Posted Date: 2018-03-21

Last Posted Date: 2024-03-27

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT03472586

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Melanoma (Skin)

Interventions: Biological: Nivolumab

First Posted Date: 2018-01-19

Last Posted Date: 2024-04-01

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 26

Registration Number: NCT03405155

Locations: 🇺🇸
Columbia University, New York, New York, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 1 locations

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Phase 2

Withdrawn

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: CPI-613
Drug: mFOLFIRNOX

First Posted Date: 2017-12-15

Last Posted Date: 2018-08-22

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT03374852

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Non-Squamous Non-Small Cell Lung Carcinoma
Stage I Non-Small Cell Lung Cancer
Stage IIB Non-Small Cell Lung Carcinoma
Stage IA Non-Small Cell Lung Carcinoma
Stage IB Non-Small Cell Lung Carcinoma
Stage IIA Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage II Non-Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Gemcitabine Hydrochloride
Drug: Cisplatin
Drug: Pemetrexed Disodium

First Posted Date: 2017-12-08

Last Posted Date: 2023-04-03

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT03366766

Locations: 🇺🇸
Abington Hospital - Jefferson Health, Abington, Pennsylvania, United States
🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Stage III Oral Cavity Squamous Cell Carcinoma
Stage IV Laryngeal Squamous Cell Carcinoma
Stage IV Oropharyngeal Squamous Cell Carcinoma
Stage IVA Hypopharyngeal Squamous Cell Carcinoma
Stage IVA Oral Cavity Squamous Cell Carcinoma
Stage IVB Laryngeal Squamous Cell Carcinoma
Stage IV Oral Cavity Squamous Cell Carcinoma
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Stage IVA Oropharyngeal Squamous Cell Carcinoma
Stage IVB Hypopharyngeal Squamous Cell Carcinoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Biological: Nivolumab

First Posted Date: 2017-11-17

Last Posted Date: 2024-04-01

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 34

Registration Number: NCT03342911

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Abington- Jefferson Health, Abington, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Automated Device for Asthma Monitoring and Management in Monitoring Adults With Lung Cancer Undergoing Radiation Therapy

Completed

Conditions: Lung Carcinoma

Interventions: Device: Monitoring Device

First Posted Date: 2017-11-13

Last Posted Date: 2024-01-08

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 24

Registration Number: NCT03340714

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Virtual Reality Education Module in Reducing Anxiety and Increasing Knowledge in Patients With Prostate Cancer Undergoing Radiation Therapy

Not Applicable

Terminated

Conditions: Prostate

Interventions: Other: Educational Intervention

First Posted Date: 2017-10-23

Last Posted Date: 2017-10-27

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 23

Registration Number: NCT03318367

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy